(Press-News.org) A single-dose oral medication called zoliflodacin shows promise as a new treatment for antibiotic-resistant gonorrhoea, according to a phase 3 clinical trial published in The Lancet. The study found that one dose of zoliflodacin was as effective as the current standard treatment, which combines two antibiotics: an injection of ceftriaxone followed by an oral dose of azithromycin.
Gonorrhoea is one of the most common sexually transmitted infections, affecting over 82 million people globally each year. However, it is increasingly difficult to treat as the bacteria that cause infection develop resistance to current antibiotics. This new medication has the potential to help slow the spread of antibiotic-resistant bacteria and make gonorrhoea treatment more accessible worldwide.
The international trial involved more than 900 people from five countries (USA, South Africa, Thailand, Belgium, and the Netherlands). Participants received either the new pill or the standard treatment. Results showed that zoliflodacin cured over 90% of infections at genital sites. The medication was well tolerated, with side effects similar to those seen with current treatments, and no serious safety issues were reported.
Zoliflodacin is currently awaiting approval from the U.S. Food and Drug Administration (FDA). If approved, the authors say it could greatly improve global efforts to control drug-resistant gonorrhea infections, support community-led care, and protect reproductive health for millions of people.
IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS:
For Article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01953-1/fulltext
For linked Comment: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02331-1/fulltext
END
The Lancet: New single dose oral treatment for gonorrhoea effectively combats drug-resistant infections, trial finds
2025-12-12
ELSE PRESS RELEASES FROM THIS DATE:
Proton therapy shows survival benefit in Phase III trial for patients with head and neck cancers
2025-12-12
At five years, 90.9% of proton patients were alive compared to 81% with traditional radiation
Proton therapy also showed benefits in quality of life, such as less feeding tube dependence, less difficulty swallowing, less dry mouth, and higher immune cell counts
Study represents the largest randomized Phase III trial comparing proton to traditional radiation with photons for oropharyngeal cancer patients
HOUSTON, DECEMBER 11, 2025 ― A new study published today in The Lancet showed a significant ...
Blood test reveals prognosis after cardiac arrest
2025-12-12
A blood biomarker yet to be used in cardiac arrest care can give a clearer picture of the extent of brain damage after a cardiac arrest. This has been shown in a large international multicentre study led by researchers at Lund University that has been published in The Lancet Respiratory Medicine. Worldwide, around four million people each year suffer a sudden cardiac arrest
“This will transform care for these patients,” says researcher Marion Moseby Knappe.
Key facts about the study: clinical prospective multicentre study // 819 patients // out-of- hospital cardiac arrest //
A simple blood test that can very accurately predict the chance of survival with good recovery ...
UBCO study finds microdosing can temporarily improve mood, creativity
2025-12-12
A new UBC Okanagan study found that people who microdose psychedelics feel better on the days they take them—but those boosts don’t seem to last.
This suggests, says Dr. Michelle St. Pierre, that perceived benefits may be acute rather than long lasting.
Dr. St. Pierre is a post-doctoral psychology researcher with UBCO’s Irving K. Barber Faculty of Arts and Sciences. She recently published a study in Psychopharmacology that tracks the daily experiences of people who microdose with psychedelics.
Microdosing involves ingesting small amounts of a psychedelic substance, commonly psilocybin mushrooms or lysergic acid diethylamide (LSD).
“Most ...
An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring treatment response in patients with bone metastases
2025-12-11
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone receptor-positive (HR+) metastatic breast cancer that has spread primarily or exclusively to the bones. These patients make up a large portion of individuals who are living with advanced breast cancer—yet are routinely excluded from clinical trials that rely on standard imaging-based assessments (i.e., RECIST 1.1). The study demonstrated that metabolic change assessed by FDG-PET/CT accurately predicted progression-free ...
Cleveland Clinic presents final results of phase 1 clinical trial of preventive breast cancer vaccine study
2025-12-11
December 11, 2025, CLEVELAND: Cleveland Clinic researchers are presenting final Phase 1 data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
The study team found that the investigational vaccine produced an immune response in the majority (74%) of all participants and was safe and well tolerated. They determined the maximum tolerated dose and described that side effects primarily consisted of mild skin inflammation at the injection site. The findings, which will inform the ...
Nationally renowned anesthesiology physician-scientist and clinical operations leader David Mintz, MD, PhD, named Chair of the Department of Anesthesiology at the UM School of Medicine
2025-12-11
University of Maryland School of Medicine Dean Mark T. Gladwin, MD, along with University of Maryland Medical Center (UMMC) President Bert O’Malley, MD, today announced the appointment of C. David Mintz, MD, PhD, to be the next Chair of the Department of Anesthesiology, and Chief of the Anesthesiology Clinical Service (“Chief of Anesthesiology”) at UMMC. Dr. Mintz, a neuroanesthesiologist and nationally recognized leader in research, education, and perioperative operations, will be installed as the Martin Helrich Endowed Professor and Chair of Anesthesiology. He will begin his new position in July, 2026.
Dr. Mintz brings an ...
Clean water access improves child health in Mozambique, study shows
2025-12-11
In Mozambique, more than one in three children under five suffer from stunting, or impaired physical growth, a sign of chronic undernutrition. New research from the University of Notre Dame shows that improving access to safe drinking water can reduce the odds of stunting by about 20 percent, making it the most effective Water, Sanitation and Hygiene (WASH) intervention for child growth.
The study, published in the journal Children, is one of the few studies to use nationally representative data from Mozambique to examine the independent and combined effects of access to water and sanitation on child growth outcomes (stunting ...
Study implicates enzyme in neurodegenerative conditions
2025-12-11
Researchers at Oregon Health & Science University have identified a type of enzyme with a complicated name — cell migration inducing and hyaluronan-binding protein, or CEMIP — is associated with disorders ranging from multiple sclerosis to stroke to neurodegenerative conditions like Alzheimer’s disease.
The next step is to develop a way to target the enzyme to heal or slow the progression of disease.
In a study published in the journal ASN Neuro, researchers describe their path to implicating CEMIP in cell culture, mice and deceased human tissue. Researchers found this specific enzyme is ...
Tufts professor named Fellow of the National Academy of Inventors
2025-12-11
James (Jim) Schwob, a professor at Tufts University School of Medicine, has been named a fellow of the National Academy of Inventors (NAI).
Election as an academy fellow is the highest professional distinction awarded solely to inventors. The NAI was founded to recognize and encourage inventors with U.S. patents and enhance the visibility of academic technology and innovation.
This year’s fellows include Nobel Prize winners and recipients of the U.S. National Medal of Technology and Innovation and Medal of Science. The group, which holds over 5,300 issued U.S. patents, includes members of the National Academies of Sciences, Engineering, and Medicine, among others.
The ...
Tiny new device could enable giant future quantum computers
2025-12-11
Researchers have made a major advance in quantum computing with a new device that is nearly 100 times smaller than the diameter of a human hair.
Published in the journal Nature Communications, the breakthrough optical phase modulators could help unlock much larger quantum computers by enabling efficient control of lasers required to operate thousands or even millions of qubits—the basic units of quantum information.
Critically, the team of scientists have developed these devices using scalable manufacturing, avoiding complex, custom builds in favor of those used to make the same technology behind ...